Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
Frontiers in Pharmacology · 18.06.2024 · 15
DOI: 10.3389/fphar.2024.1382256 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.06.2024. Verfasst von Ziwei Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the cancers that seriously threaten human health. Immunotherapy serves as the mainstay of treatment for HCC patients by targeting the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis. However, the effectiveness of anti-PD-1/PD-L1 treatment is limited when HCC becomes drug-resistant. Tumor-associated macrophages (TAMs) are an important factor in the negative regulation of PD-1 antibody targeted therapy in the tumor microenvironment (TME). Therefore, as an emerging direction in cancer immunotherapy research for the treatment of HCC, it is crucial to elucidate the correlations and mechanisms between TAMs and PD-1/PD-L1-mediated immune tolerance. This paper summarizes the effects of TAMs on the pathogenesis and progression of HCC and their impact on HCC anti-PD-1/PD-L1 immunotherapy, and further explores current potential therapeutic strategies that target TAMs in HCC, including eliminating TAMs in the TME, inhibiting TAMs recruitment to tumors and functionally repolarizing M2-TAMs (tumor-supportive) to M1-TAMs (antitumor type).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.
Zitieren
APA
Li, Z., Duan, D., Li, L., Peng, D., Ming, Y., Ni, R., & Liu, Y. (2024). Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1382256
Vancouver
Li Z, Duan D, Li L, Peng D, Ming Y, Ni R, et al. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1382256
BibTeX
@article{Li2024,
author = {Li, Ziwei and Duan, Dongyu and Li, Li and Peng, Dan and Ming, Yue and Ni, Rui and Liu, Yao},
title = {Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1382256}
}
EUVIMED